Wednesday, 14 October 2026European Markets

ELKEM And IMCD Have A High Dividend Yield And Return On Equity In The Specialty Chemicals Industry.

Loading stream...

(VIANEWS) - ELKEM (ELK.OL) is among this list of stock assets with the highest dividend rate and return on equity on the Specialty Chemicals industry.

Financial Asset Price Forward Dividend Yield Return on Equity
ELKEM (ELK.OL) kr22.60 25.91% 19.37%
IMCD (IMCD.AS) €122.20 1.91% 17.66%

Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. ELKEM (ELK.OL)

25.91% Forward Dividend Yield and 19.37% Return On Equity

Elkem ASA provides silicones, silicon products, and carbon solutions worldwide. The company offers silicones polymers, including chlorosilanes and silicone oils; silicone elastomers, comprising liquid silicone rubber, heat cured rubber, and RTV-1 and RTV-2 silicones; and silicone fluids, such as silicone resin, silicone compounds, silicone grease, and silicone emulsion. It also provides silicon based materials comprising silicon, silicon powder/micronized silicon, silica fume/ microsilica, ferrosilicon, grain refiner, silicon and boron carbide, ferrosilicon nitride, fused silica, polymer additives, and specialties for refractories. In addition, the company offers foundry alloys, such as foundry alloys, preconditioners, recarburizers, conditioners, nodularizers, inserts, and inoculants; and carbon based materials comprising furnace tapping materials, cathode ramming paste, furnace lining materials, electrode paste, and prebaked and other electrodes. The company was founded in 1904 and is headquartered in Oslo, Norway. Elkem ASA is a subsidiary of Bluestar Elkem International Co., Ltd. S.A.

Earnings Per Share

As for profitability, ELKEM has a trailing twelve months EPS of kr7.76.

PE Ratio

ELKEM has a trailing twelve months price to earnings ratio of 2.91. Meaning, the purchaser of the share is investing kr2.91 for every norwegian krone of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 19.37%.

More news about ELKEM.

2. IMCD (IMCD.AS)

1.91% Forward Dividend Yield and 17.66% Return On Equity

IMCD N.V. distributes, markets, and sells specialty chemicals and ingredients in the Netherlands, rest of Europe, the Middle East, Africa, North America, South America, and the Asia-Pacific. The company offers bioactives, biocides, chelates, functional additives, rheology modifiers, silicones, solubilisers, and solvents; active pharmaceutical, agrochemicals, biopharma, excipients and formulation, nutraceuticals, and regulated synthesis; actives, UV sunscreens, rheology modifiers, thickeners, surfactants, emulsifiers, emollients, elastomers, humectants, waxes, film formers, functional powders, hair styling polymers, hair conditioners, solvents, solubilizers, pigments, pearls, colorants, opacifiers, pearlisers, preservatives, antioxidants, additives, fragrances, and essential oils; and resins and binders, additives, functional fillers, and specialty solvents. It also provides taste, texture, nutrition, and function; base oil, fuel addictive, lubricants addictive, lubricants finished fluids, solvents, degreasers and fuel, compounds, and upstream, midstream and downstream oil, gas and energy; bio-based chemicals, binders, corrosion inhibitors, catalysts, intermediates, monomers, organic building blocks, processing aids, reactive diluents, solvents, and surfactants. IMCD N.V. was founded in 1995 and is headquartered in Rotterdam, the Netherlands.

Earnings Per Share

As for profitability, IMCD has a trailing twelve months EPS of €5.15.

PE Ratio

IMCD has a trailing twelve months price to earnings ratio of 23.73. Meaning, the purchaser of the share is investing €23.73 for every euro of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 17.66%.

Revenue Growth

Year-on-year quarterly revenue growth declined by 1.3%, now sitting on 4.59B for the twelve trailing months.

Moving Average

IMCD's worth is under its 50-day moving average of €130.02 and way below its 200-day moving average of €139.53.

More news about IMCD.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com